Death toll rises to 45 in Sigachi Industries explosion in Hyderabad
The deceased was identified as 45-year-old Tarak from West Bengal, who suffered over 75% burn injuries in the June 30 explosion that ripped through the dryer unit of the firm located in Pashamylaram of Sangareddy district. Arrangements were made by district authorities to send the deceased's body to his native place. Currently, four more patients are undergoing treatment at the same hospital, with one of them, Rajesh Kumar Chowdary (42) from Bihar, being on a non-invasive ventilator (HIV).
The condition of the other three is stable, according to doctors.
Meanwhile, another two victims, Videshi Kahar (48) and Ganga Mukhiya (38), both of whom suffered from 40% burns, were declared stable and were discharged from another private hospital in Patancheru on Monday. Eight people are still untraced from the incident.
You Can Also Check:
Hyderabad AQI
|
Weather in Hyderabad
|
Bank Holidays in Hyderabad
|
Public Holidays in Hyderabad
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 hours ago
- The Hindu
Pre-marriage HIV/AIDS test could be made mandatory in Meghalaya
Meghalaya may follow Goa in making HIV/AIDS test mandatory for all before marriage, the State's Health and Family Welfare Minister Mazel Ampareen Lyngdoh said on Friday (July 25, 2025). She said an 'alarming' overview of the HIV/AIDS scenario in the State by the Meghalaya AIDS Control Society (MACS) had led the government to consider a new law to make such a test compulsory. 'We should have a set of laws like Goa to make pre-marriage HIV/AIDS test mandatory. This will benefit our communities,' Ms. Lyngdoh told journalists in the State's capital, Shillong. On Thursday, Deputy Chief Minister Prestone Tynsong chaired a meeting with the agenda of formulating a comprehensive HIV/AIDS policy. The Health Minister said her department was directed to prepare a Cabinet note for the policy. She said the meeting was specific to the East Khasi Hills district, which recorded 3,432 HIV-positive cases in 2024, almost twice as many as the year before. Of these, only 1,581 were availing of anti-retroviral therapy (ART). 'We will hold meetings in other regions of the State to develop area-specific strategies in consultation with bureaucrats and medical professionals,' Ms. Lyngdoh said, pointing out that the number of positive cases was highest in the Jaintia Hills region. 'We must ensure that everyone who has been tested is brought into the treatment system because HIV/AIDS is not fatal if treated properly,' Ms. Lyngdoh said. According to MACS, unprotected sex is the primary cause of transmission of the virus in the State.
NDTV
2 hours ago
- NDTV
EU Regulator Approves Twice-Yearly Injectable Drug For HIV Prevention
LONDON: The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission. In a statement on Friday, the EU drug regulator said its evaluations of lenacapavir, sold as Yeytuo in Europe by Gilead Sciences, showed the drug is "highly effective" and "considered to be of major public health interest." Once the regulator's guidance is accepted by the European Commission, the authorization is valid in all 27 EU member countries as well as Iceland, Norway and Liechtenstein. Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping transmission in both women and men. Winnie Byanyima, executive director of the U.N. AIDS agency, has said the drug "could change the trajectory of the HIV epidemic" if it is made available to everyone who needs it. In June, the U.S. Food and Drug Administration authorized lenacapavir to prevent HIV. Earlier this month, the World Health Organization recommended countries offer the drug as an additional option to people at risk of the virus. Condoms help guard against HIV infection if used properly. Other medication aimed at preventing HIV include daily pills that people can take and another injectable drug called cabotegravir, which is given every two months. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more visits to health clinics or stigma from taking daily pills. Critics have raised concerns, however, that lenacapavir may not be made widely enough available to stop global outbreaks of HIV. Drugmaker Gilead has said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates - mostly in Africa, Southeast Asia and the Caribbean. But it has excluded nearly all of Latin America, where rates are far lower but increasing, sparking concern the world is missing a critical opportunity to stop the disease. Last year, there were about 630,000 AIDS deaths worldwide and more than 40 million people are estimated to have HIV, according to UNAIDS. UNAIDS chief Byanyima has previously suggested the US President Donald Trump make a deal with Gilead to produce and license its "magical" prevention drug lenacapavir across the world to the millions of people who need it.
Time of India
6 hours ago
- Time of India
Lakshmi Kalyani Chinthala: A rising force in AI-Driven healthcare analytics and innovation
Lakshmi Kalyani Chinthala is fast becoming a recognisable name at the intersection of artificial intelligence, healthcare innovation, and predictive business analytics. Her recent contributions are turning heads in global research communities, particularly for her work on scalable and intelligent diagnostic systems tailored to support public health and enterprise strategy. Among her most impactful innovations is HIVSense-Econ, a unified model that merges diagnostic intelligence with real-time economic forecasting. Designed to support NGOs, health organisations, and policymakers, it uses wearable biosensors and edge AI to deliver on-demand HIV diagnostics while simultaneously generating predictive health economics data. This novel approach enables smarter policy decisions, streamlined treatment access, and resource allocation that is both responsive and equitable. Chinthala brings a socially driven approach to technological advancement. Her work emphasises diagnostic equity, workplace wellness, and the ethical deployment of AI systems. She proposes that dynamic, mobile, and cost-effective diagnostics have transformative potential across sectors ranging from public health infrastructure to corporate HR and insurance planning. Her professional recognition is steadily growing. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Brain tumor has left my son feeling miserable; please help! Donate For Health Donate Now Undo She has served as a reviewer and judge at several international conferences, contributed to research across multidisciplinary domains, and maintains author profiles on reputed databases. Her published works focus on digital health innovation, AI-integrated business models, and the practical application of biosensor technologies. She is involved in judging master's theses and conference proceedings from across the globe. What distinguishes Chinthala's work is her commitment to building systems that are not only innovative but also actionable. HIVSense-Econ, for instance, is designed for use in both developed and underserved healthcare settings, allowing for adaptive deployment based on infrastructure constraints. The system links health data with predictive analytics, making it possible for stakeholders to anticipate medical trends and act proactively rather than reactively. Chinthala is part of a new wave of health-tech researchers who see AI not just as a tool for efficiency but as a force for public good. Her vision blends technology with compassion, ensuring that innovations do not just reach the privileged few but serve broader societal needs. As industries and governments begin to embrace AI for health strategy, diagnostics, and operational planning, Lakshmi Kalyani Chinthala stands at the forefront — a thought leader shaping the next generation of intelligent and inclusive healthcare systems.
